- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Binding domains.
Displaying page 1 of 1.
EudraCT Number: 2021-005713-13 | Sponsor Protocol Number: 21102 | Start Date*: 2022-08-16 | |||||||||||
Sponsor Name:ACELYRIN, INC. | |||||||||||||
Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa | |||||||||||||
Medical condition: Hidradenitis Suppurativa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003405-94 | Sponsor Protocol Number: ABY-035-202 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:ACELYRIN, Inc. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a... | |||||||||||||
Medical condition: Active Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004373-50 | Sponsor Protocol Number: 369852 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of treatment with Semaglutide on cognitive function, neuroinflammation and hepatic nitrogen metabolism in patients with non-alcoholic steatohepatitis: A randomized placebo-controlled trial | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004964-25 | Sponsor Protocol Number: ABY-035-203 | Start Date*: 2021-05-21 | |||||||||||
Sponsor Name:Affibody AB | |||||||||||||
Full Title: A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis (L... | |||||||||||||
Medical condition: non-infectious intermediate, posterior, or pan-uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003176-16 | Sponsor Protocol Number: ADP-0055-003/GOG-3084 | Start Date*: 2023-07-03 |
Sponsor Name:Adaptimmune LLC | ||
Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) | ||
Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006498-49 | Sponsor Protocol Number: 21103 | Start Date*: 2022-08-18 | |||||||||||||||||||||
Sponsor Name:ACELYRIN, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis | |||||||||||||||||||||||
Medical condition: Non-infectious, Intermediate-, Posterior- or Pan-uveitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019634-26 | Sponsor Protocol Number: MPEX-209 | Start Date*: 2011-05-24 | ||||||||||||||||
Sponsor Name:Mpex Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients | ||||||||||||||||||
Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) FR (Ongoing) IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004404-19 | Sponsor Protocol Number: Acadmed18013 | Start Date*: 2014-05-07 | |||||||||||
Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pul... | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005802-24 | Sponsor Protocol Number: ADP-0055-002 | Start Date*: 2022-03-21 | |||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||
Full Title: A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers | |||||||||||||
Medical condition: advanced esophageal or esophagogastric junction (EGJ) cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000589-39 | Sponsor Protocol Number: ADP-0044-002 | Start Date*: 2020-02-13 | |||||||||||||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||||||||||||
Full Title: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
Medical condition: Advanced Synovial Sarcoma Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
